SecBot SecBot
8-K ·Filed Nov 5, 2026

SANA

Sana Biotechnology, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 11h ago SEC0001193125-26-449791
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The GAAP net income is entirely driven by a non-cash fair value adjustment from the Cobalt amendment, not operational improvement. Monitor the SC451 IND filing and SG293 clinical data in 2027 as key catalysts; cash runway into mid-2027 suggests no near-term financing urgency but burn rate remains elevated.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$2.37
T+0 close · Nov 5, 2026 · via day close
Latest settled
−14.77%
T+5 · $2.02 · next T+20 in 20d
Vs SPY
−17.36%
α at T+5
Latest observation
−19.72%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $2.37entry
  2. T+1 · 8d ago +4.01%α +1.64% · $2.47
  3. T+5 · 4d ago −14.77%α −17.36% · $2.02
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sana Biotechnology reported Q3 2026 GAAP net income of $20.4 million ($0.07 per share), driven by a $63.4 million non-cash gain from the August 2026 amendment to the Cobalt contingent consideration, versus a net loss of $42.2 million in Q3 2025. Cash position fell to $121.7 million from $138.4 million at year-end 2025, with non-GAAP operating cash burn of $103.4 million for nine months. The company continues to advance SC451 and SG293 toward clinical trials, with IND filing for SC451 expected later this year and SG293 data in first half of 2027.

Key Financial Metrics

EPS (Adj.)
−$0.14
GAAP: $0.07

Key Facts

  • Q3 2026 GAAP net income of $20.4 million ($0.07 per share) vs net loss of $42.2 million ($0.16 per share) in Q3 2025
  • Non-GAAP net loss of $43.0 million ($0.14 per share) vs $39.0 million ($0.15 per share) in Q3 2025
  • Cash, cash equivalents and marketable securities of $121.7 million as of September 30, 2026, down from $138.4 million at December 31, 2025
  • Non-GAAP operating cash burn of $103.4 million for nine months ended September 30, 2026 vs $108.0 million in prior year period
  • R&D expenses of $33.9 million in Q3 2026 vs $30.1 million in Q3 2025, driven by SC451 and SG293 manufacturing costs
  • Non-cash gain of $63.4 million from change in fair value of success payment liabilities and contingent consideration, including $55.5 million from Cobalt contingent consideration amendment in August 2026
  • Cash runway expected into mid-2027
  • SC451 IND and Phase 1/2 trial expected as early as this year; SG293 first-in-human data expected in first half of 2027

Financial Impact

GAAP net income of $20.4 million driven by $63.4 million non-cash gain from Cobalt contingent consideration amendment; non-GAAP net loss of $43.0 million; cash burn of $103.4 million YTD

net incomecash positionoperating cash burnR&D expenses

Risk Factors

  • Cash burn of $103.4 million YTD with $121.7 million remaining implies potential need for additional capital before mid-2027 if burn rate continues
  • SC451 and SG293 are still pre-clinical; clinical trial delays or negative data would remove key catalysts
  • Non-GAAP net loss of $43.0 million in Q3 2026 is wider than $39.0 million in Q3 2025, indicating rising operating costs

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-449791
Document: sana-20261105.htm0001193125-26-449791
Document: 0001193125-26-449791-index-headers.html0001193125-26-449791
Document: 0001193125-26-449791-index.html0001193125-26-449791
Document: 0001193125-26-449791.txt0001193125-26-449791
8-K Data (Synthetic)0001193125-26-449791

Track record

12 reports on SANA

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $2.37 Now $1.88 −20.68% settles Dec 7
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
  3. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  4. Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
  5. May 11, 202627w ago 8-K Neutral 4/10 No price data
  6. May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  8. Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  9. Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
  10. Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026